RCUS Q4 2023 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RCUSArcus Biosciences, Inc.

$2B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$31M-7.9% YoY

Gross Profit

$31M100.0% margin

Operating Income

-$91M-293.5% margin

Net Income

-$81M-261.3% margin

EPS (Diluted)

$-1.08

QoQ Revenue Growth

-3.1%

Cash Flow

Operating Cash Flow

-$88M

Free Cash Flow

-$94M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$633M

Stockholders' Equity

$462M

Cash & Equivalents

$127M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$31M	$34M	-7.9%
Gross Profit	$31M	$34M	-7.9%
Operating Income	-$91M	-$74M	-22.2%
Net Income	-$81M	-$67M	-20.1%

Revenue Segments

Other Collaboration Revenue

$9M100%